These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 28499374

  • 1. Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.
    Chantarogh S, Vilaiyuk S, Tim-Aroon T, Worawichawong S.
    BMC Nephrol; 2017 May 12; 18(1):159. PubMed ID: 28499374
    [Abstract] [Full Text] [Related]

  • 2. Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.
    Gupta A, Bagri NK, Tripathy SK, Barwad A, Phulware RH, Hari P.
    Rheumatol Int; 2020 Jan 12; 40(1):153-159. PubMed ID: 31273457
    [Abstract] [Full Text] [Related]

  • 3. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP.
    Arthritis Res Ther; 2017 Nov 22; 19(1):256. PubMed ID: 29166924
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of an early response-based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis.
    Dey S, Roy D, Sinhamahapatra P, Ghosh A.
    Int J Rheum Dis; 2024 May 22; 27(5):e15196. PubMed ID: 38769886
    [Abstract] [Full Text] [Related]

  • 5. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C.
    Pediatr Rheumatol Online J; 2019 Aug 22; 17(1):57. PubMed ID: 31438986
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
    J Rheumatol; 2014 Apr 22; 41(4):759-67. PubMed ID: 24634205
    [Abstract] [Full Text] [Related]

  • 9. Systemic onset juvenile idiopathic arthritis: a single center experience.
    Sağ E, Uzunoğlu B, Bal F, Sönmez HE, Demir S, Bilginer Y, Özen S.
    Turk J Pediatr; 2019 Apr 22; 61(6):852-858. PubMed ID: 32134578
    [Abstract] [Full Text] [Related]

  • 10. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C, Mesquida M, Adán A, Anton J, Ramanan AV, Carreno E, Mackensen F, Kotaniemi K, de Boer JH, Bou R, de Vicuña CG, Heiligenhaus A.
    J Rheumatol; 2016 Dec 22; 43(12):2183-2188. PubMed ID: 27633821
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S.
    J Rheumatol; 2015 Apr 22; 42(4):712-22. PubMed ID: 25684767
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Systemic Juvenile Idiopathic Arthritis with Amyloidosis: An Uncommon Complication with a Favourable Outcome.
    Sharma A, Gupta A, Mitra S, Nada R, Bhattad S, Singh S.
    Indian J Pediatr; 2016 May 22; 83(5):477-8. PubMed ID: 26442699
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.
    Brunner HI, Chen C, Bovis F, De Benedetti F, Espada G, Joos R, Akikusa J, Chaitow J, Boteanu AL, Kimura Y, Rietschel C, Siri D, Smolewska E, Schmeling H, Brown DE, Martini A, Lovell DJ, Huang B, Ruperto N, Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.
    Arthritis Care Res (Hoboken); 2021 Sep 22; 73(9):1264-1274. PubMed ID: 32702212
    [Abstract] [Full Text] [Related]

  • 18. Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.
    Park EH, Lee EY, Shin K, Kim HA.
    Rheumatol Int; 2020 May 22; 40(5):791-798. PubMed ID: 31598752
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.